Clinical trials: Renal Carcinoma
Renal Cell Carcinoma
RNA-Loaded Dendritic Cell Cancer Vaccine
The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of administering a dendritic cell vaccine to patients with metastatic renal cell carcinoma.
- Trial name
- NCT00087984
- Testing
- MB-002
- Where
- 5 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Argos Therapeutics
Kidney Cancer
Biomarkers in Urine Samples From Patients With Wilms Tumor
RATIONALE: Studying samples of urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer. PURPOSE: This clinical trial studies biomarkers in urine from patients with Wilms tumor.
- Trial name
- NCT01550393
- Testing
- proteomic profiling, enzyme-linked immunosorbent assay, laboratory biomarker analysis
- Volunteers
- 100 people
- Sponsor
- Children's Oncology Group
Non-Clear Cell Renal Cell Carcinoma
Personalized ctDNA Monitoring for Predicting Immunotherapy Outcomes in Advanced Non-Clear Cell Renal Cell Carcinoma
This is a prospective, non-interventional observational cohort study evaluating the clinical utility of patient-specific circulating tumor DNA (ctDNA) monitoring in patients with advanced non-clear cell renal cell carcinoma…
- Trial name
- NCT07776483
- Testing
- Patient-Specific Tumor-Informed ctDNA Monitoring
- Volunteers
- 67 people
- Sponsor
- West China Hospital
Renal Cell Carcinoma
Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma
BKM-120 is a drug that may slow the growth of cancer cells. This drug has been used in laboratory experiments and information from those research studies suggests that this drug may help to slow the growth of renal cancer cells.
- Trial name
- NCT01283048
- Testing
- BKM-120 Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Toni Choueiri, MD
Carcinoma, Renal Cell
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
This was a first in human study of DFF332, a small molecule that targets a protein called HIF2α. By acting on HIF2α, DFF332 may be able to stop the growth of certain types of cancer.
- Trial name
- NCT04895748
- Testing
- DFF332, RAD001, PDR001
- Where
- 11 sites in United States, Czechia and 5 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Urothelial Carcinoma
BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma
BIBF1120 in patients with advanced FGFR3 mutated, FGFR3 overexpressed, or FGFR3 wild type urothelial carcinoma of urinary bladder, urethra, ureter, and renal pelvis and who have failed platinum-based chemotherapy.
- Trial name
- NCT02278978
- Testing
- BIBF1120
- Where
- Taiwan
- Volunteers
- 129 people
- Sponsor
- National Taiwan University Hospital
Renal Cancer, Renal Secondary Cancer
Stereotactic Body RadioTherapy With Continuous Tracking for Primary and Secondary Renal Cancer
This is a prospective, interventional, monocentric, clinical study of Stereotactic Body Radiation Therapy (SBRT) for primary or secondary renal tumors, delivering from 25-26 Gy/1 fraction to 42-48 Gy/3-4 fractions or 40-50 Gy/5…
- Conditions
- Renal Cancer, Renal Secondary Cancer, Stereotactic Body Radiotherapy
- Trial name
- SBRTRC (NCT07285538)
- Testing
- Stereotactic body radiotherapy (SBRT)
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS San Raffaele
Pediatric Oncology
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Dose escalation phase of the study : To define the safety profile, maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of regorafenib administered orally as a single agent in a 3-weeks-on/1- week-off schedule in…
- Trial name
- NCT02085148
- Testing
- Regorafenib (BAY73-4506), Vincristine (Cellcristin®), Irinotecan (Irinotecan Cell pharm®)
- Where
- 12 sites in France, Italy and 2 more
- Volunteers
- 62 people
- Sponsor
- Bayer
Metastatic Renal Cell Carcinoma (mRCC)
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Patients with metastatic renal cell carcinoma (mRCC) who failed first-line therapy with sunitinib or pazopanib was treated with everolimus. Efficacy and safety of everolimus was evaluated in these patients.
- Trial name
- NCT01514448
- Testing
- Everolimus (RAD001)
- Where
- 13 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Novartis Pharmaceuticals
Urothelial Carcinoma, Urethral Neoplasms
Cabozantinib for Advanced Urothelial Cancer
Background: Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It is approved for medullary thyroid cancer. However, studies have shown that prostate and ovarian tumors respond to it.
- Conditions
- Urothelial Carcinoma, Urethral Neoplasms, Urinary Bladder Neoplasms, Kidney Neoplasms
- Trial name
- NCT01688999
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Cystic Renal Disease, Kidney Cancer
Comparison of Surgery and Active Surveillance in the Treatment of Bosniak III Renal Cysts
The incidence of renal cysts is rising due to increased abdominal imaging. Renal complicated cysts have been traditionally classified according to the Bosniak classification, which distinguishes cystic masses by specific features…
- Conditions
- Cystic Renal Disease, Kidney Cancer, Surgery
- Trial name
- NCT04670887
- Testing
- Delayed surgery, Immediate surgery
- Volunteers
- 200 people
- Sponsor
- Helsinki University Central Hospital
Renal Cell Carcinoma, Soft Tissue Sarcoma
HYPAZ: Hypertension Induced by Pazopanib
Pazopanib is a new cancer drug that works by limiting the growth of new blood vessels in tumours. About half of patients who take pazopanib develop high blood pressure (hypertension).
- Conditions
- Renal Cell Carcinoma, Soft Tissue Sarcoma, Glioblastoma, Ovarian Cancer
- Trial name
- HYPAZ (NCT01392352)
- Testing
- Pazopanib
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma
The purpose of this study is to learn if a vaccine made from the patient's own tumor cells, then genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), will delay or stop the growth of the…
- Conditions
- Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT00258687
- Testing
- GVAX
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Perioperative Anesthetic, Renal Cancer
Impact of Perioperative Anesthetic Management on Renal Cancer Progression.
The relationship between perioperative drugs, including preoperative medications, anesthetics, and analgesics, and postoperative outcomes in cancer patients is a complex and evolving field of study.
- Trial name
- NCT06536244
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
Metastatic Cancer, Melanoma Cancer
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Drugs called checkpoint inhibitors help the immune system fight cancer. When the effectiveness of these drugs wears off, it may be possible to renew their effectiveness by combining it with a special type of radiation therapy…
- Conditions
- Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer
- Trial name
- NCT03693014
- Testing
- Stereotactic Body Radiotherapy, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
- Where
- 10 sites in United States
- Volunteers
- 69 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Renal Cancer
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
The primary objectives of this Phase 1b/2 study were as follows: Phase 1b (Bolus and Infusion): To evaluate the safety and tolerability of carfilzomib in patients with relapsed solid tumors and in patients with relapsed and/or…
- Conditions
- Ovarian Cancer, Renal Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT00531284
- Testing
- Carfilzomib, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 184 people
- Sponsor
- Amgen
Renal Cell Adenocarcinoma, Clear Cell Renal Carcinoma
AMG 172 First in Human Study in Patients With Kidney Cancer
This is the first-in-human (Phase I) study of AMG 172, an antibody drug conjugate (ADC), in subjects with kidney cancer [Clear Cell Renal Cell Carcinoma (ccRCC)] who have relapsed or who have refractory disease following at least…
- Conditions
- Renal Cell Adenocarcinoma, Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT01497821
- Testing
- AMG 172
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 37 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma
Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy
This phase II trial studies how well autologous tumor infiltrating lymphocytes (LN-145) and pembrolizumab work in treating patients with transitional cell cancer that cannot be removed by surgery or has spread to other places in…
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma
- Trial name
- NCT03935347
- Testing
- Cyclophosphamide, Fludarabine, Fludarabine Phosphate
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.